超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Pacira  
是專注于臨床和商業發展的新產品，滿足急性保健醫生和病人的需求一個新興的專業制藥公司。該公司目前的重點是術后疼痛控制的非阿片類產品的發展，商業EXPAREL?（布比卡因注射脂質體懸浮液），其主導產品，在2012年4月在美國推出。 EXPAREL和兩個其他市售產品利用Pacira專有產品交貨技術DepoFoam?封裝在不改變其分子結構的藥物，然后釋放超過所需的時間內，一個獨特的平臺。

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients.

A Focus on Pain Management

Our primary focus lies in the development of non-opioid products for postsurgical pain control. We believe we have the technology to improve products' efficacy and safety and make a critical difference to patients in terms of dosing frequency and administration.

Now Available: EXPAREL? (bupivacaine liposome injectable suspension) is a non-opioid local analgesic indicated for administration into the surgical site to produce postsurgical analgesia. EXPAREL combines bupivacaine with the DepoFoam? drug delivery platform to provide postsurgical pain control with a single intraoperative infiltration.
Our proven product delivery technology, DepoFoam, is a multivesicular liposome technology that encapsulates drugs without altering their molecular structure and then releases them over a desired time period (from 1 to 30 days); it has been used to reduce the dosing frequency and extend the duration of action of DepoCyt(e)? and DepoDur? for over a decade.